Skip Navigation



European Heart Journal Advance Access published online on November 21, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn513
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
30/1/25    most recent
ehn513v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jansson, A. M.
Right arrow Articles by Caidahl, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jansson, A. M.
Right arrow Articles by Caidahl, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Prognostic value of circulating chromogranin A levels in acute coronary syndromes

Anna M. Jansson1,2,{dagger}, Helge Røsjø3,4,{dagger}, Torbjørn Omland3,4, Thomas Karlsson5, Marianne Hartford5,6, Allan Flyvbjerg7 and Kenneth Caidahl1,8,9,*

1 Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
2 Department of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden
3 Department of Medicine, Akershus University Hospital, Lørenskog, Norway
4 Faculty Division Akershus University Hospital, University of Oslo, Oslo, Norway
5 Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
6 AstraZeneca R&D, Mölndal, Sweden
7 The Medical Research Laboratories, Medical Department M (Diabetes and Endocrinology), Clinical Institute, Aarhus University Hospital, Aarhus, Denmark
8 Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden
9 Department of Clinical Physiology, Karolinska University Hospital N2:01, SE-171 76 Stockholm, Sweden

Received 29 March 2008; revised 12 October 2008; accepted 23 October 2008.

* Corresponding author. Tel: +46 8 517 77 510, Fax: +46 8 51773800, Email: kenneth.caidahl{at}ki.se

Aims: To determine whether circulating levels of chromogranin A (CgA) provide prognostic information independently of conventional risk markers in acute coronary syndromes (ACSs).

Methods and results: We measured circulating CgA levels on day 1 in 1268 patients (median age 67 years, 70% male) with ACS admitted to a single coronary care unit of a Scandinavian teaching hospital. The merit of CgA as a biomarker was evaluated after adjusting for conventional cardiovascular risk factors. During a median follow-up of 92 months, 389 patients (31%) died. The baseline CgA concentration was strongly associated with increased long-term mortality [hazard ratio per 1 standard deviation increase in logarithmically transformed CgA level: 1.57 (1.44–1.70), P < 0.001], heart failure hospitalizations [1.54 (1.35–1.76), P < 0.001], and recurrent myocardial infarction (MI) [1.27 (1.10–1.47), P < 0.001], but not stroke. After adjustment for conventional cardiovascular risk markers, the association remained significant for mortality [hazard ratio 1.28 (1.15–1.42), P < 0.001] and heart failure hospitalization [hazard ratio 1.24 (1.04–1.47), P = 0.02], but not recurrent MI.

Conclusion: CgA is an independent predictor of long-term mortality and heart failure hospitalizations across the spectrum of ACSs and provides incremental prognostic information to conventional cardiovascular risk markers.

Key Words: Acute coronary syndromes • Chromogranin A • Troponin T • Echocardiography • Prognosis

{dagger} These two authors have contributed equally to the work.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
W. Jeske and P. Glinicki
Prognostic value of circulating chromogranin A levels in acute coronary syndrome
Eur. Heart J., November 11, 2009; (2009) ehp468v1.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
H. Rosjo, T. Omland, A. M. Jansson, K. Caidahl, and A. Flyvbjerg
Prognostic value of circulating chromogranin A levels in acute coronary syndrome: reply
Eur. Heart J., November 11, 2009; (2009) ehp469v1.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome.
J. Am. Coll. Cardiol., October 13, 2009; 54(16): 1544 - 1555.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.